Refine
Has Fulltext
- yes (41)
Year of publication
Document Type
- Journal article (39)
- Book (2)
Language
- English (41)
Keywords
- Fabry disease (4)
- consortium (4)
- genetic modifiers (3)
- investigators (3)
- Box-Jenkins-Verfahren (2)
- Box–Jenkins Program (2)
- Fabry nephropathy (2)
- Frequency Domain (2)
- SAS <Programm> (2)
- State-Space Models (2)
- Time Series Analysis (2)
- Zeitreihenanalyse (2)
- Zustandsraummodelle (2)
- anxiety (2)
- cardiomyopathy (2)
- chronic kidney disease (2)
- common variants (2)
- education (2)
- genome-wide association (2)
- hypertrophic cardiomyopathy (2)
- ischemic stroke (2)
- modifiers (2)
- ovarian cancer (2)
- prospective (2)
- radiotherapy (2)
- single-nucleotide polymorphisms (2)
- survival (2)
- susceptibility loci (2)
- A-delta fibers (1)
- ALS treatment (1)
- Alpha-Galactosidase (1)
- Alzheimer’s disease (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anderson-Fabry Disease (1)
- BRCA1/2 (1)
- CRISPR-Cas Systems (1)
- CXCL10 (1)
- Cardiac dysfunction| Brain natriuretic peptide (1)
- Cimex lectularius (1)
- D313Y genotype (1)
- DNA (1)
- DNA damage (1)
- DNA double strand breaks (1)
- DNA methylation (1)
- Enzyme replacement therapy (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Fabry cardiomyopathy (1)
- Fabry patient (1)
- Fabry-associated pain (1)
- Galactosidase-A gene (1)
- Genotype–phenotype correlations (1)
- Heart failure (1)
- Histologic grade (1)
- IFNG (1)
- Induced Pluripotent Stem Cells (1)
- K-region (1)
- Kidney function (1)
- LV mass (1)
- Lag time (1)
- MTB (1)
- Male breast cancer (1)
- NEIL2 (1)
- Natural-history data (1)
- OGG1 (1)
- Outcome survey (1)
- Ovarian (1)
- Pain (1)
- Pain-related evoked potentials (1)
- Pathology (1)
- QuantiFERON\(^®\)-TB Gold Plus (1)
- RESP model (1)
- RT-qPCR (1)
- Racial differences (1)
- STS (1)
- Small fiber neuropathy (1)
- Stroke (1)
- T-Track\(^®\) TB (1)
- TB (1)
- Troponin (1)
- VEMP (1)
- ZNF365 (1)
- [18F]FDG-PET-CT (1)
- \(\gamma\)h2ax (1)
- abdominal lymph node metastases (1)
- accuracy (1)
- active TB (1)
- alleles (1)
- alpha/delta agonist GFT505 (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anticoagulation (1)
- assistive devices (1)
- astrogliosis (1)
- atherogenic dyslipidaemia (1)
- atrial fibrillation (1)
- bed bug (1)
- biomarkers (1)
- biosynthesis (1)
- blended learning (1)
- blood lymphocytes (1)
- breast cancer (1)
- bridging (1)
- brucei (1)
- cadherins (1)
- cancer (1)
- cancer care (1)
- candidate genes (1)
- cardiac dysfunction (1)
- cardiac hypertrophy (1)
- cardiac rehabilitation (1)
- cardiogenetics (1)
- cardiovascular munster procam (1)
- caregiver burden (1)
- cell (1)
- cerebral ischemia (1)
- chemistry (1)
- chemotherapy (1)
- chip-seq (1)
- clinical skills (1)
- cornea verticillata (1)
- coronary artery disease (1)
- crithidia fasciulata (1)
- cryptogenic stroke (1)
- damage (1)
- decreasing autonomy (1)
- depression (1)
- diabetic mouse (1)
- e-Learning (1)
- echocardiography (1)
- ejection fraction (1)
- elements (1)
- enzyme replacement therapy (1)
- epigenetics (1)
- exercise training (1)
- expression signature (1)
- extinction (1)
- feasibility (1)
- female (1)
- foci (1)
- frailty (1)
- functional status (1)
- gender (1)
- genetic interaction networks (1)
- genetic variants (1)
- genetics (1)
- genome (1)
- haplogroups (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hearing loss (1)
- heart failure (1)
- heterozygote (1)
- high denisty lipoprotein (1)
- histone H2AX (1)
- home-based-rehabilitation (1)
- hormone-related protein (1)
- human ectoparasite (1)
- humans (1)
- immune check inhibitor (1)
- in vivo (1)
- in vivo imaging (1)
- individual radiosensitivity (1)
- infection detection (1)
- informal caregiving (1)
- inherited metabolic disorders (1)
- left ventricular mass (1)
- leishmaniasis (1)
- low-molecular heparin (1)
- luminescence (1)
- lymph node (1)
- lysosomal storage disorder (1)
- mRNA (1)
- mammographic density (1)
- medical device training (1)
- mesoscopics (1)
- metabolism (1)
- middle aged (1)
- migration (1)
- mitochondria (1)
- molecular diagnostics (1)
- monoamine oxidase A (1)
- multicentric (1)
- multiple diseases (1)
- neck cancer (1)
- neurodevelopmental disorders / genetics (1)
- neuroprotection (1)
- neurorepair (1)
- nitrate and thyroid carcinogenesis (1)
- non-interventional (1)
- old patients (1)
- oral mucositis (1)
- oral squamous cell carcinoma (1)
- oropharyngeal carcinoma (1)
- orylation (1)
- outcomes research (1)
- outreach (1)
- oxidative stress (1)
- pN1 (1)
- parathyroid carcinoma (1)
- patient access (1)
- pediatric thyroid cancer after Chernobyl and Fukushima (1)
- pembrolizumab (1)
- phospholipid fatty acids (1)
- phosphorylation (1)
- physical activity (1)
- placebo-controlled trial (1)
- point-of-care echocardiography (1)
- polycyclic aromatic hydrocarbons (1)
- polymorphism (1)
- population (1)
- postoperative bleeding (1)
- precision oncology (1)
- progression-free survival (1)
- psychological interventions (1)
- psychological support (1)
- purification (1)
- quality of life (1)
- quality of life (QoL) (1)
- radiosensitivity (1)
- randomized controlled-trial (1)
- real world data (1)
- rectal cancer (1)
- redox (1)
- renal dysfunction (1)
- renal fibrosis (1)
- repair (1)
- repeated surgery (1)
- resection (1)
- residual cardiovascular risk (1)
- rising incidence of thyroid cancer (1)
- sarcoma (1)
- scientific guidelines (1)
- screening and overdiagnosis (1)
- secondary prevention (1)
- selection (1)
- septal hypertrophy (1)
- small vessel disease (1)
- socioeconomic status (1)
- stroke unit (1)
- subtypes (1)
- superconductivity (1)
- surgery (1)
- susceptibility (1)
- susceptibility alleles (1)
- symptom-specific treatment (1)
- system (1)
- systolic dysfunction (1)
- targeted gene panel (1)
- tele-medicine (1)
- term fenofibrate therapy (1)
- therapeutic options (1)
- thromboembolism (1)
- topological insulators (1)
- trabectedin (1)
- translational research (1)
- triglyceride-rich lipoproteins (1)
- troponin (1)
- trypanosoma cruzi (1)
- tuberculosis (1)
- tumor subtypes (1)
- type 2 diabetes (1)
- type-2 diabetes mellitus (1)
- urinary protein excretion (1)
- variants (1)
- vascular dementia (1)
- vertigo (1)
- whole exome sequencing (1)
- young patients (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Medizinische Klinik und Poliklinik I (11)
- Institut für Humangenetik (9)
- Neurologische Klinik und Poliklinik (7)
- Institut für Klinische Epidemiologie und Biometrie (4)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (3)
- Medizinische Klinik und Poliklinik II (3)
- Institut für Mathematik (2)
- Institut für Pharmazie und Lebensmittelchemie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
Sonstige beteiligte Institutionen
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7 x 10(-8), HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 x 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 x 10(-8), HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2 x 10(-4)). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%-50% compared to 81%-100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.